Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of YL242 monotherapy in advanced solid tumors
CTR20253635Phase 2Active
- Sponsor
- MediLink Therapeutics
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of YL242 in Nonhematologic neoplasms, sponsored by MediLink Therapeutics. Started Oct 2025; status: active.
02
Drugs
YL242
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20253635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253635.